Alliance Global Partners initiated coverage of Curaleaf Holdings (CSE:CURA) with a “buy” rating and price target of $14 (Canadian). The stock closed at $8.56 on Feb. 10. “We view Curaleaf as well-positioned to succeed...
SVB Leerink initiated coverage of Abeona Therapeutics (NASDAQ:ABEO) with an “outperform” rating and $6 price target. The stock closed at $2.51 on Feb. 7. “Abeona is a clinical stage gene therapy company with a realistic...
Maxim Group launched coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and price target of $1. The stock closed at 26 cents on Feb. 5. Heat is developing lead asset, ImPACT, a cell-based immune therapy for...
Maxim Group initiated coverage of Armata Pharmaceuticals (NYSE American:ARMP) with a “buy” rating and $8 price target. The stock closed at $3.71 on Feb. 5. Armata is developing phage therapies for the treatment of...
Piper Sandler launched coverage of Itamar Medical (NASDAQ:ITMR) with an “overweight” rating and $22 price target. The stock closed at $16 on Feb. 4. Itamar makes home sleep testing products that are used to diagnose...
Brookline Capital Markets initiated coverage of BioCeres Crop Solutions (NASDAQ:BIOX) with a “buy” rating and $13 price target. The stock closed at $4.95 on Feb. 4. BioCeres is the market leader in South America...
Ladenburg Thalmann raised its price target for Avadel Pharmaceuticals (NASDAQ:AVDL) to $14 from $8 after the company completed enrollment in its REST-ON Phase 3 study, with a pivotal data readout expected in the second...
H.C. Wainwright launched coverage of Harpoon Therapeutics (NASDAQ:HARP) with a “buy” rating and $28 price target. The stock closed at $13.29 on Jan. 31. Harpoon is advancing a proprietary platform of redirected T cell...
Stifel initiated coverage of AdaptHealth (NASDAQ:AHCO) with a “buy” rating and $17 price target. The stock closed at a 52-week high of $13 on Jan. 30. “AdaptHealth is a unique asset poised to capitalize on an ongoing...
H.C. Wainwright lowered its price target for Iterum Therapeutics (NASDAQ:ITRM) to $9 from $14 after the company unveiled a $52-million private placement of exchangeable and royalty-linked subordinated notes earlier this...